{"id":61514,"date":"2026-03-27T12:19:22","date_gmt":"2026-03-27T04:19:22","guid":{"rendered":"https:\/\/flcube.com\/?p=61514"},"modified":"2026-03-27T12:26:23","modified_gmt":"2026-03-27T04:26:23","slug":"grand-pharma-2025-revenue-hkd-12-28b-innovative-products-hit-50-of-sales-radiopharma-soars-61","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61514","title":{"rendered":"Grand Pharma 2025 Revenue HKD 12.28B \u2013 Innovative Products Hit 50% of Sales, Radiopharma Soars 61%"},"content":{"rendered":"\n

Grand Pharmaceutical Group Co., Ltd.<\/strong> (HKG: 0512<\/a>) reported 2025 financial results<\/strong>, with revenue rising 5.5% YoY to HKD 12.28 billion (USD 1.084 billion)<\/strong> \u2013 14.8% growth excluding VBP impact<\/strong>. The company achieved a transformation milestone<\/strong> as innovative barrier products reached ~50% of revenue<\/strong> (vs. 40% prior year). The radiopharmaceutical oncology segment surged 61.0% to HKD 950 million (RMB 839 million)<\/strong> \u2013 a 15-fold increase over four years<\/strong> \u2013 anchored by YiGanTai (SIR-Spheres Y-90)<\/strong>, now the world’s only FDA-approved dual-indication selective internal radiation therapy<\/strong> for hepatocellular carcinoma (HCC) and colorectal cancer liver metastases<\/strong>.<\/p>\n\n\n\n

Financial Highlights<\/h2>\n\n\n\n
Metric<\/th>2025 Result<\/th>YoY Change<\/th>Adjusted Growth<\/th>Strategic Significance<\/th><\/tr><\/thead>
Total Revenue<\/strong><\/td>HKD 12.28B (USD 1.084B)<\/td>+5.5%<\/td>+14.8% (ex-VBP)<\/strong><\/td>VBP headwinds masking underlying innovation strength<\/td><\/tr>
Innovative Products<\/strong><\/td>~50% of revenue<\/strong><\/td>+10pp mix shift<\/td>\u2014<\/td>Transformation milestone<\/strong> \u2013 majority revenue from innovation<\/td><\/tr>
Radiopharma Segment<\/strong><\/td>HKD 950M (RMB 839M)<\/td>+61.0%<\/strong><\/td>15x over 4 years<\/td>High-growth engine<\/strong> \u2013 oncology diagnosis + therapy<\/td><\/tr>
YiGanTai Global Position<\/strong><\/td>Dual FDA indications<\/strong> (HCC + CRC liver mets)<\/td>First and only<\/td>\u2014<\/td>World leadership<\/strong> in selective internal radiation therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Radiopharmaceutical Pipeline Progress<\/h2>\n\n\n\n
Asset<\/th>Target\/Indication<\/th>2025 Milestone<\/th>Strategic Value<\/th><\/tr><\/thead>
YiGanTai<\/strong> (SIR-Spheres Y-90)<\/td>HCC + colorectal liver metastases<\/td>FDA dual approval<\/strong> \u2013 world’s first<\/td>Commercial anchor<\/strong> \u2013 61% segment growth driver<\/td><\/tr>
GPN02006<\/strong><\/td>HCC diagnostic RDC \u2013 GPC-3 target<\/strong><\/td>Development ongoing<\/td>World’s first<\/strong> GPC-3 HCC diagnostic \u2013 imaging companion to YiGanTai<\/td><\/tr>
GPN01530<\/strong><\/td>FAP-targeting \u2013 solid tumors<\/td>FDA Phase I\/II approval<\/strong><\/td>Next-gen radioligand therapy<\/strong> \u2013 broad tumor applicability<\/td><\/tr>
TLX591-CDx<\/strong><\/td>PSMA-targeting \u2013 prostate cancer imaging<\/td>China Phase III primary endpoint met<\/strong>; NDA accepted by NMPA<\/strong><\/td>Near-term China revenue<\/strong> \u2013 diagnostic imaging expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context: Innovation Transformation<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
VBP Impact Mitigation<\/strong><\/td>14.8% ex-VBP growth<\/strong> demonstrates innovation portfolio resilience<\/strong> vs. generic pricing pressure<\/td><\/tr>
Radiopharma Differentiation<\/strong><\/td>Theranostics platform<\/strong> (diagnosis + therapy) \u2013 GPC-3 imaging + Y-90 therapy<\/strong> creates integrated HCC management<\/strong><\/td><\/tr>
Global Regulatory Leadership<\/strong><\/td>FDA dual indication<\/strong> for YiGanTai validates world-class development<\/strong>; supports ex-China expansion<\/strong><\/td><\/tr>
Pipeline Depth<\/strong><\/td>4 radiopharmaceutical assets<\/strong> in development \u2013 sustainable growth engine<\/strong> beyond YiGanTai maturation<\/td><\/tr>
Revenue Mix Target<\/strong><\/td>50% innovative products<\/strong> achieved; 60%+ target by 2027<\/strong> via radiopharma and biologics expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n